Loong E P, Tam P P, Chiu T T, Chan M Y, Panesar N S, Lau J
Department of Obstetrics and Gynaecology, Faculty of Medicine, Chinese University of Hong Kong, Shatin.
Asia Oceania J Obstet Gynaecol. 1990 Dec;16(4):297-300. doi: 10.1111/j.1447-0756.1990.tb00352.x.
Fifteen patients who had had previous unsuccessful in vitro fertilization and embryo transfer (IVF) cycles were treated with intranasal buserelin, a gonadotropin releasing hormone agonist (GnRH-a), commencing in the mid-luteal phase prior to ovarian stimulation in the next cycle. The use of buserelin was associated with the suppression of spontaneous luteinizing hormone (LH) surges (nil versus 6), an increase in gonadotropin requirements (27.3 versus 13.7 ampoules), higher serum estradiol peak levels (8, 154 versus 4,446 pmol/l), more oocytes retrieved (87 versus 20) as well as more embryos being transferred (28 versus 7). In buserelin-treated cycles, 2 pregnancies resulted but no oocyte was recovered in 2 of the 3 poor responders.
15名先前体外受精和胚胎移植（IVF）周期未成功的患者，在下一周期卵巢刺激前的黄体中期开始接受鼻内布舍瑞林治疗，布舍瑞林是一种促性腺激素释放激素激动剂（GnRH-a）。使用布舍瑞林与自发性促黄体生成素（LH）高峰的抑制有关（从6次降至0次），促性腺激素需求量增加（从13.7支增加到27.3支），血清雌二醇峰值水平更高（从4446pmol/l升至8154pmol/l），回收的卵母细胞更多（从20个增加到87个）以及移植的胚胎更多（从7个增加到28个）。在接受布舍瑞林治疗的周期中，有2例妊娠，但3例反应较差的患者中有2例未回收卵母细胞。
